Ankündigung • May 18
Synergy CHC Corp. Announces Notice Of Non-Compliance With Minimum Bid Price Requirement From Nasdaq Synergy CHC Corp. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to November 11, 2026. If the Company does not regain compliance by November 11, 2026, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company intends to monitor the closing bid price of the Company's common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with other applicable Nasdaq listing requirements. Ankündigung • Apr 21
Synergy CHC Corp., Annual General Meeting, Jun 29, 2026 Synergy CHC Corp., Annual General Meeting, Jun 29, 2026. Ankündigung • Apr 02
Synergy CHC Corp. announced delayed annual 10-K filing On 04/01/2026, Synergy CHC Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. New Risk • Mar 31
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-US$8.3m). High level of non-cash earnings (82% accrual ratio). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Profit margins are more than 30% lower than last year (7.5% net profit margin). Market cap is less than US$100m (US$13.6m market cap). Ankündigung • Mar 18
Synergy CHC Corp. to Report Q4, 2025 Results on Mar 31, 2026 Synergy CHC Corp. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2026 Ankündigung • Feb 27
Synergy CHC Corp. announced that it expects to receive $31.3 million in funding Synergy CHC Corp. announced a private placement of Common Shares of the company to raise gross proceeds of $31,300,000 on February 27, 2026. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to US$1.30, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 19x in the Personal Products industry in the US. Total returns to shareholders of 337% over the past three years. Ankündigung • Dec 17
Synergy CHC Corp. Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico &Latin America Synergy CHC Corp. announced that Pedro Colmenares has been appointed Director of Sales &Marketing for Mexico &Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. As Director of Sales and Marketing for Mexico and Latin America, he will play a central role in executing this strategy and driving growth across both the Companys supplement and functional beverage portfolios, building a scalable commercial foundation to support long-term growth. Mr. Colmenares is a senior commercial executive with over 18 years of experience across the pharmaceutical, nutraceutical, OTC, and consumer health sectors. He has successfully led market entry and expansion initiatives throughout Mexico and Latin America, consistently transforming underdeveloped markets into high-performing, sustainable businesses. His background includes leadership roles at Procter &Gamble and Victus/Megalabs, where he built scaled regional sales, marketing, and distribution platforms through strategic partnerships and omnichannel execution. Throughout his career, Mr. Colmenares has launched and developed operations in multiple countries across Latin America, driving accelerated growth through disciplined go-to-market strategies, localized brand development, and strong retailer and supplier relationships. His experience spans both multinational and regional organizations, providing a deep understanding of the operational and cultural dynamics required to scale consumer health brands in the region. Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$1.84, the stock trades at a trailing P/E ratio of 8x. Average forward P/E is 14x in the Personal Products industry in the US. Total loss to shareholders of 65% over the past year. Ankündigung • Nov 27
Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $5.69 million. Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $5.69 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Nov 16
Third quarter 2025 earnings released: EPS: US$0.012 (vs US$0.10 in 3Q 2024) Third quarter 2025 results: EPS: US$0.012 (down from US$0.10 in 3Q 2024). Revenue: US$8.01m (up 12% from 3Q 2024). Net income: US$125.3k (down 84% from 3Q 2024). Profit margin: 1.6% (down from 11% in 3Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Personal Products industry in the US. Ankündigung • Oct 31
Synergy CHC Corp. to Report Q3, 2025 Results on Nov 13, 2025 Synergy CHC Corp. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025 Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to US$2.69, the stock trades at a trailing P/E ratio of 9.3x. Average forward P/E is 15x in the Personal Products industry in the US. Board Change • Sep 25
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Nitin Kaushal was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 23
Synergy CHC Corp. Announces Management Appointments Synergy CHC Corp. announced two key leadership changes: Scott Woodburn has been appointed to Head of Strategic Partnerships to drive the Company’s expansion in functional beverages, and Teresa Thompson has been appointed to Synergy’s Board of Directors (the “Board”), effective immediately. In connection with Woodburn’s new role, he has resigned from the Board. Thompson will also serve on the Audit, Compensation, and Nominating and Corporate Governance Committees, filling the positions previously held by Woodburn.Scott Woodburn, who has served on Synergy’s Board since October 2024, brings over 30 years of executive leadership across the global beverage and consumer goods industries. A former Vice President of National and Global Accounts at Coca-Cola, he has led international brand growth, executed large-scale sales strategies, and built enduring partnerships with major retail and QSR chains. He also leads a beverage-focused consulting firm, serves as an advisor to investment bank Silverwood Partners, and most recently held the role of SVP of Sales at Fuling USA. With a proven track record scaling Fortune 500 brands, Woodburn is set to accelerate Synergy’s beverage innovation and market expansion in the rapidly growing $100B+ global energy and wellness drinks market. Synergy has appointed Teresa Thompson to its Board of Directors, filling the vacancy created by Woodburn’s transition. Thompson is a seasoned retail executive with nearly four decades of experience at Costco Wholesale, including 29 years as a Pharmacy OTC Buyer. In that role, she oversaw the vitamins and supplements categories for Costco’s U.S. warehouses, managing vendor relationships, optimizing product assortments, and implementing strategic initiatives that enhanced the customer experience. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$2.56, the stock trades at a trailing P/E ratio of 8.8x. Average forward P/E is 15x in the Personal Products industry in the US. Total returns to shareholders of 7.6% over the past year. New Risk • Aug 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 48% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-US$12m). High level of non-cash earnings (84% accrual ratio). Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$23.4m market cap). Ankündigung • Aug 26
Synergy CHC Corp. has completed a Follow-on Equity Offering in the amount of $4.375 million. Synergy CHC Corp. has completed a Follow-on Equity Offering in the amount of $4.375 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,750,000
Price\Range: $2.5
Discount Per Security: $0.175 Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to US$2.90, the stock trades at a trailing P/E ratio of 8.5x. Average forward P/E is 16x in the Personal Products industry in the US. Ankündigung • Aug 16
Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $4.999999 million. Synergy CHC Corp. has filed a Follow-on Equity Offering in the amount of $4.999999 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,275,510
Price\Range: $3.92 Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: US$0.17 (vs US$0.087 in 2Q 2024) Second quarter 2025 results: EPS: US$0.17 (up from US$0.087 in 2Q 2024). Revenue: US$8.13m (up 1.4% from 2Q 2024). Net income: US$1.47m (up 125% from 2Q 2024). Profit margin: 18% (up from 8.2% in 2Q 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in the US. Recent Insider Transactions • Aug 03
CEO & Chairman recently bought US$80k worth of stock On the 30th of July, Jack Ross bought around 28k shares on-market at roughly US$2.85 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jack has been a buyer over the last 12 months, purchasing a net total of US$2.9m worth in shares. Ankündigung • Aug 01
Synergy CHC Corp. to Report Q2, 2025 Results on Aug 14, 2025 Synergy CHC Corp. announced that they will report Q2, 2025 results Pre-Market on Aug 14, 2025 Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$3.61, the stock trades at a trailing P/E ratio of 13.4x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 203% over the past year. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to US$3.24, the stock trades at a trailing P/E ratio of 12.1x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 4,850% over the past three years. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to US$2.65, the stock trades at a trailing P/E ratio of 9.9x. Average forward P/E is 22x in the Personal Products industry in the US. Total returns to shareholders of 3,949% over the past three years. Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$2.07, the stock trades at a trailing P/E ratio of 7.7x. Average forward P/E is 23x in the Personal Products industry in the US. Total returns to shareholders of 3,063% over the past three years. New Risk • May 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$16m). High level of non-cash earnings (83% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (7.2% net profit margin). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$17.7m market cap). Reported Earnings • May 15
First quarter 2025 earnings released: EPS: US$0.10 (vs US$0.077 in 1Q 2024) First quarter 2025 results: EPS: US$0.10 (up from US$0.077 in 1Q 2024). Revenue: US$8.17m (down 13% from 1Q 2024). Net income: US$876.3k (up 51% from 1Q 2024). Profit margin: 11% (up from 6.2% in 1Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Personal Products industry in the US. Valuation Update With 7 Day Price Move • May 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to US$1.77, the stock trades at a trailing P/E ratio of 7.1x. Average forward P/E is 19x in the Personal Products industry in the US. Total returns to shareholders of 2,875% over the past three years. Ankündigung • May 02
Synergy CHC Corp. to Report Q1, 2025 Results on May 15, 2025 Synergy CHC Corp. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025 Ankündigung • Apr 19
Synergy CHC Corp., Annual General Meeting, Jun 18, 2025 Synergy CHC Corp., Annual General Meeting, Jun 18, 2025. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 40% After last week's 40% share price gain to US$2.50, the stock trades at a trailing P/E ratio of 10.1x. Average forward P/E is 16x in the Personal Products industry in the US. Total returns to shareholders of 6,903% over the past three years. New Risk • Apr 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$17m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.1% net profit margin). Market cap is less than US$100m (US$19.7m market cap). Reported Earnings • Mar 31
Full year 2024 earnings released: EPS: US$0.28 (vs US$0.84 in FY 2023) Full year 2024 results: EPS: US$0.28 (down from US$0.84 in FY 2023). Revenue: US$34.8m (down 19% from FY 2023). Net income: US$2.12m (down 67% from FY 2023). Profit margin: 6.1% (down from 15% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the US. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$3.02, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Personal Products industry in the US. Total returns to shareholders of 12,589% over the past three years. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorates as stock falls 28% After last week's 28% share price decline to US$3.02, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 21x in the Personal Products industry in the US. Total returns to shareholders of 22,971% over the past three years. Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to US$4.15, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 26x in the Personal Products industry in the US. Total returns to shareholders of 31,604% over the past three years. Ankündigung • Nov 27
Synergy CHC Corp. to Report Q3, 2024 Results on Dec 06, 2024 Synergy CHC Corp. announced that they will report Q3, 2024 results Pre-Market on Dec 06, 2024 Ankündigung • Oct 25
Synergy CHC Corp. Common Stock Deleted from OTC Equity Synergy CHC Corp. Common Stock has been deleted from OTC Equity effective October 23, 2024, due to Market Center Change Listed on NASDAQ. Ankündigung • Oct 23
Synergy CHC Corp. has completed an IPO in the amount of $10.35 million. Synergy CHC Corp. has completed an IPO in the amount of $10.35 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,150,000
Price\Range: $9
Discount Per Security: $0.63 Ankündigung • Jun 28
Synergy CHC Corp. has filed an IPO in the amount of $23 million. Synergy CHC Corp. has filed an IPO in the amount of $23 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: New Market Listing Ankündigung • Jul 18
Synergy CHC Files Form 15 Synergy CHC Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock, par value $0.00001 per share. 
